- In January 2025, the U.S. NIH launched a collaborative consortium project focused on evaluating the efficacy and safety of therapeutic T-cell vaccines specifically targeting EBV-related Hodgkin lymphoma. This initiative involves multiple cancer research centers and aims to offer a more targeted and durable treatment option for patients with EBV-driven lymphomas.
- In October 2024, Roche initiated Phase II clinical trials of a novel small-molecule antiviral drug designed to inhibit EBV DNA polymerase, a key enzyme involved in viral replication. The compound is intended to suppress EBV reactivation and reduce disease progression in associated conditions.
- In July 2024, a UK-based academic research group reported encouraging interim findings from a prophylactic EBV vaccine trial involving university students. The vaccine demonstrated strong immune responses and potential for preventing primary EBV infection in young adults, a population particularly vulnerable to infectious mononucleosis.
- In April 2024, Pfizer announced the development of a next-generation antibody-drug conjugate (ADC) engineered to selectively target EBV-transformed lymphocytes. The ADC combines a monoclonal antibody directed at EBV-related antigens with a potent cytotoxic agent, aiming to destroy infected cells while minimizing damage to healthy tissue.
